MALAT1 and colorectal carcinoma: For example, MALAT1 conferred oxaliplatin resistance to CRC via the miR-218/EZH2 axis by promoting EMT formation, suggesting that lncRNA, as well as members of the lncRNA-related ceRNA crosstalk, could be therapeutic targets for CRC [104].